Innate Pharma S.A.

NASDAQ:IPHA

Biotechnology

Healthcare
$1.03 +1.91%

+$0.03 today

Market cap
$115.05M
Beta
0.89
P/E (TTM)
-3.0
EPS (TTM)
-$0.54
52W Low $1.17High $2.63

Volume 0.50M

Average 0.07M

IPHA Long-term Investments

Investments the company intends to hold for more than a year.

Innate Pharma S.A.NASDAQ: IPHA

Long-term Investments · Q4 FY2025 · quarter ended Dec 2025

Long-term investments rises 4.1% from a year ago

Long-term investments stood at €10.7M at the end of Q4 FY2025, up 4.1% from a year earlier. Over 3 fiscal years it compounded at -32.7% a year.

Context

  • Long-term investments amounted to 17.1% of total assets at the end of Q4 FY2025, up 7.8 pp from a year earlier.
  • Long-term investments increased in 2 of the last 3 fiscal years.

What to watch

Whether long-term investments keeps rising in the next quarterly balance sheet after a +4.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
€10.7M— QoQ
Last fiscal yearDec 2025
€10.7M+4.1% YoY
Year agoDec 2024
€10.28M+4.1% since
Long-term Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.1%——
1 year+4.1%——
3-year CAGR-32.7%——
5-year CAGR——
10-year CAGR——

Long-term Investments history

EUR · from the balance sheet

Latest · FY2025
10.7M EUR
Year-over-year change
+4.1%
4-year CAGR
-28.0%

Long-term Investments vs competitors

How IPHA compares with its peers on the latest reported figures

  • Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
  • Long-term investments amounts to 17.1% of total assets for IPHA, versus a peer median of 0.0%.
IPHA Competitors
Long-term Investments for IPHA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPHAInnate Pharma S.A.Dec 2025€10.7M EUR+4.1%-32.7%17.1%
CGENCompugen Ltd.Mar 2026$452K USD——0.3%
NVCTNuvectis Pharma, Inc.Mar 2026$0 USD——0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.Mar 2026$0 USD——0.0%
MISTMilestone Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
CRDFCardiff Oncology, Inc.Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.Mar 2026$0 USD——0.0%
ELTXElicio Therapeutics, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding IPHA) ———0.0%

Competitors are the stored peer set for IPHA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents103.76M84.23M70.61M66.4M28.08M
Short-term Investments16.08M17.26M21.85M14.37M6.22M
Net Receivables1.66M3.14M46.49M1.64M7.61M
Inventory00000
Other Current Assets11.81M27.88M00(4.28K)
Total Current Assets138.26M139.83M148.01M85.74M46.69M
Property, Plant & Equipment (Net)10.17M8.54M6.32M5.13M4.35M
Goodwill2K(41M)000
Intangible Assets44.19M42.55M416K00
Long-term Investments39.88M35.12M9.8M10.28M10.7M
Tax Assets5.03M8.57M9.01M00
Other Non-current Assets29.97M14.25M1.64M9.9M946.6K
Total Non-current Assets129.24M68.03M27.18M25.32M16M
Total Assets267.5M207.86M175.19M111.06M62.69M
Account Payables14.73M13.66M8.56M7.92M15.04M
Short-term Debt29.94M1.26M8.45M8.44M8.52M
Tax Payables7.46M5.98M7.02M6.96M0
Deferred Revenue12.5M6.56M5.87M616K2.82M
Other Current Liabilities21.91M19.02M7.82M7.65M9.97M
Total Current Liabilities79.89M41.34M39.64M32.98M36.63M
Long-term Debt11.49M38.93M30.61M22.18M13.67M
Deferred Tax Liabilities5.03M8.57M9.01M00
Deferred Revenue (Non-current)25.41M7.92M4.62M2.83M0
Other Non-current Liabilities36.23M55.74M39.07M44.13M33.99M
Total Non-current Liabilities80.17M112.37M83.65M69.24M47.75M
Total Liabilities160.06M153.71M132.29M102.23M84.39M
Common Stock3.98M4.01M4.04M4.19M4.69M
Retained Earnings(272.21M)(330.32M)(336.89M)(386.36M)(435.36M)
Accumulated OCI456K819K495K27K1.12M
Other Stockholders Equity(1K)0000
Minority Interest00000
Total Equity107.44M54.15M51.9M8.83M(21.69M)
Total Debt44.25M42.25M39.89M31M22.56M
Net Debt(59.51M)(41.97M)(30.71M)(35.4M)(5.52M)

Innate Pharma S.A.

NASDAQ:IPHA

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.